Pfizer Introduces OAB Drug Detrusitol to Japan.Tokyo, Japan, June 7, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Pfizer Japan announced on June 6 that it will launch Detrusitol Capsule 2mg/4mg (tolterodine tartrate tartrate /tar·trate/ (tahr´trat) a salt of tartaric acid. tar·trate n. A salt or ester of tartaric acid. tartrate a salt of tartaric acid. ), its proprietary agent for treating overactive bladder (OAB OAB Ordem dos Advogados do Brasil (Brazil) OAB Offline Address Book OAB Over-Active Bladder (urology) OAB Outlook Address Book (Microsoft) OAB Ocean Affairs Board ), on June 8. The new product, which is a muscarinic muscarinic /mus·ca·rin·ic/ (mus?kah-rin´ik) denoting the cholinergic effects of muscarine on postganglionic parasympathetic neural impulses. receptor antagonist, can exert beneficial effects with once-a-day dosage. Initially launched in 1997, the agent is prescribed to 10 million people in over 80 countries worldwide. In 2005, Pfizer posted sales of $10 billion, and has more than a 50% share in the OAB drug market. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion